Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | NQO1 | P15559 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 2/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2068642 | 0.85 | TLR8 (0.38) | HPGDSMN1; SMN2KDM4EALDH1A1MAPT | |
| SCHEMBL2067563 | 0.80 | HPGD (0.43) | HPGDSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL3428317 | 0.78 | HPGD (0.42) | HPGDSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL2067406 | 0.78 | HPGD (0.42) | HPGDSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL15822203 | 0.78 | HPGD (0.42) | HPGDSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL1023680 | 0.78 | MAPT (0.42) | HPGDKDM4EALDH1A1MAPTL3MBTL1 | |
| SCHEMBL2069192 | 0.77 | HPGD (0.41) | HPGDSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL2068711 | 0.76 | HPGD (0.40) | HPGDSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL2066560 | 0.74 | HPGD (0.39) | HPGDSMN1; SMN2CA12CA1CA2 | |
| SCHEMBL2068145 | 0.74 | HPGD (0.39) | HPGDSMN1; SMN2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48622-E1 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB Biopharma SRL (BE) | 2021-07-06 | — | — | US | claimed |
| EP-3157922-B1 | PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2018-11-28 | — | — | EP | claimed |
| US-10087180-B2 | Pyrazolo-pyridine derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-10-02 | — | — | US | claimed |
| US-20180201622-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-07-19 | — | — | US | claimed |
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BY) | 2018-06-19 | — | — | US | claimed |
| US-9969748-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | UCB BIOPHARMA SPRL (BE) | 2018-05-15 | — | — | US | claimed |
| EP-2935269-B1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2018-04-11 | — | — | EP | claimed |
| US-9714248-B2 | Therapeutically active pyrazolo-pyrimidine derivatives | UCB PHARMA SA (BE) | 2017-07-25 | — | — | US | claimed |
| US-20170129905-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2017-05-11 | — | — | US | claimed |
| US-20170121324-A1 | Pyrazolo-Pyridine Derivatives as Kinase Inhibitors | UCB BIOPHARMA SPRL (BE) | 2017-05-04 | — | — | US | claimed |
| US-20170121337-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-05-04 | — | — | US | claimed |
| EP-3157922-A1 | PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2017-04-26 | — | — | EP | claimed |
| EP-3157924-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2017-04-26 | — | — | EP | claimed |
| EP-3157923-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB Biopharma SPRL (BE) | 2017-04-26 | — | — | EP | claimed |
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | UCB PHARMA SA (BE) | 2016-07-07 | — | — | US | claimed |
| WO-2015193168-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | claimed |
| WO-2015193169-A1 | FUSED BICYCLIC HETEROAROMATIC DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | claimed |
| WO-2015193167-A1 | PYRAZOLO-PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB BIOPHARMA SPRL (BE) | 2015-12-23 | — | — | WO | claimed |
| EP-2935269-A1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB Biopharma SPRL (BE) | 2015-10-28 | — | — | EP | claimed |
| WO-2014096423-A1 | THERAPEUTICALLY ACTIVE PYRAZOLO-PYRIMIDINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2014-06-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201622-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | HPGD 4029/4885SMN1; SMN2 4781/4885CA12 4584/4885 |
| US-20160194329-A1 | Therapeutically Active Pyrazolo-Pyrimidine Derivatives | HAVCR2, TPMT, NFATC1 | HPGD 1449/4885SMN1; SMN2 2651/4885CA12 4666/4885 |
| US-10087180-B2 | Pyrazolo-pyridine derivatives as kinase inhibitors | PI4KA, PI4KB, PI4K2A | HPGD 3914/4885SMN1; SMN2 4652/4885CA12 4835/4885 |
| US-20170121337-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | HPGD 4089/4885SMN1; SMN2 4803/4885CA12 4659/4885 |
| US-20170129905-A1 | Fused Bicyclic Heteroaromatic Derivatives as Kinase Inhibitors | PI4KB, PI4KA, PI4K2B | HPGD 4029/4885SMN1; SMN2 4781/4885CA12 4584/4885 |
| US-10000497-B2 | Fused bicyclic heteroaromatic derivatives as kinase inhibitors | PI4KB, PI4KA, PI4K2B | HPGD 4089/4885SMN1; SMN2 4803/4885CA12 4659/4885 |
| US-20170121324-A1 | Pyrazolo-Pyridine Derivatives as Kinase Inhibitors | PI4KA, PI4KB, PI4K2A | HPGD 3914/4885SMN1; SMN2 4652/4885CA12 4835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.